Protagonist Therapeutics (United States)

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

Sheila Ranganath, Ashok Bhandari, Nicole Avitahl-Curtis et al. · PLoS ONE · 2015 · 42 citations · Full text

Immunology, Kda Polyethylene Glycol, Neutralizing Activity +17

PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis

William J. Sandborn, Larry Mattheakis, Nishit B. Modi et al. · Gastroenterology · 2021 · 35 citations · Full text

Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial

Kris V. Kowdley, Nishit B. Modi, Kevork Peltekian et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 35 citations

Iron Metabolism, Iron Overload, Hematology +8

Preclinical Serological Signatures are Associated With Complicated Crohn’s Disease Phenotype at Diagnosis

Rok Seon Choung, Francesca Petralia, Joana Torres et al. · Clinical Gastroenterology and Hepatology · 2023 · 27 citations · Full text

Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients.

Ronald Hoffman, Yelena Ginzburg, Marina Kremyanskaya et al. · Journal of Clinical Oncology · 2022 · 20 citations

Hematological Malignancy, Immunohematology, Thrombosis +12